Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Letter: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.

Hadziyannis SJ.

Aliment Pharmacol Ther. 2016 Sep;44(5):537-8. doi: 10.1111/apt.13715. No abstract available.

2.

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen.

Hadziyannis SJ.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1499-501. doi: 10.1016/j.cgh.2016.06.015. Epub 2016 Jun 23. No abstract available.

PMID:
27339695
3.

Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population.

Gbandi E, Goulas A, Sevastianos V, Hadziyannis S, Panderi A, Koskinas J, Papatheodoridis G, Vasiliadis T, Agapakis D, Protopapas A, Ioannidou P, Zacharakis G, Sinakos E, Koutsounas S, Germanidis G.

Pharmacol Rep. 2016 Apr;68(2):476-82. doi: 10.1016/j.pharep.2015.10.009. Epub 2015 Nov 6.

PMID:
26922556
4.

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.

Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A.

J Viral Hepat. 2016 Feb;23 Suppl 1:1-12. doi: 10.1111/jvh.12493.

PMID:
26809941
5.

Update on Hepatitis B Virus Infection: Focus on Treatment.

Hadziyannis SJ.

J Clin Transl Hepatol. 2014 Dec;2(4):285-91. doi: 10.14218/JCTH.2014.00026. Epub 2014 Dec 15. Review.

6.

Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

Chang ML, Liaw YF, Hadziyannis SJ.

Aliment Pharmacol Ther. 2015 Aug;42(3):243-57. doi: 10.1111/apt.13272. Epub 2015 Jun 10. Review.

7.
8.

Letter: safe and effective cessation of long-term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg-negative chronic hepatitis B.

Hadziyannis SJ.

Aliment Pharmacol Ther. 2015 Jan;41(2):236-7. doi: 10.1111/apt.13040. No abstract available.

9.

Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B.

Hadziyannis S, Liaw YF.

Gut. 2015 Jun;64(6):1005-6. doi: 10.1136/gutjnl-2014-308677. Epub 2014 Nov 19. No abstract available.

PMID:
25410164
10.

Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection?

Hadziyannis SJ, Laras A, Hadziyannis E.

Aliment Pharmacol Ther. 2014 May;39(10):1250-1. doi: 10.1111/apt.12719. No abstract available.

11.

Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.

Hadziyannis E, Hadziyannis SJ.

Expert Rev Gastroenterol Hepatol. 2014 Feb;8(2):185-95. doi: 10.1586/17474124.2014.876362. Review.

PMID:
24417264
12.

The natural course of chronic hepatitis B virus infection and its management.

Hadziyannis SJ, Vassilopoulos D, Hadziyannis E.

Adv Pharmacol. 2013;67:247-91. doi: 10.1016/B978-0-12-405880-4.00007-X. Review.

PMID:
23886003
13.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.

J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.

PMID:
23872601
14.

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC.

J Viral Hepat. 2013 Aug;20(8):524-9. doi: 10.1111/jvh.12074. Epub 2013 Mar 3.

PMID:
23808990
15.

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.

Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR.

Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23.

16.

Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.

Hadziyannis SJ, Sevastianos V.

Aliment Pharmacol Ther. 2013 Feb;37(4):491. doi: 10.1111/apt.12175. No abstract available.

17.

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.

Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S.

J Viral Hepat. 2012 Nov;19(11):766-74. doi: 10.1111/j.1365-2893.2012.01624.x. Epub 2012 May 14.

PMID:
23043383
18.

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.

Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M.

Expert Opin Drug Saf. 2012 Nov;11(6):901-9. doi: 10.1517/14740338.2012.721927. Epub 2012 Sep 4.

PMID:
22943161
19.

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.

Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E.

Gastroenterology. 2012 Sep;143(3):629-636.e1. doi: 10.1053/j.gastro.2012.05.039. Epub 2012 May 31.

PMID:
22659218
20.

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.

Lee SS, Roberts SK, Berak H, Dusheiko GM, Harley HA, Gane EJ, Husa P, Horsmans YJ, Hadziyannis SJ, Jenny Heathcote E, Messinger D, Tatsch F, Han KH, Ferenci P.

Liver Int. 2012 Sep;32(8):1270-7. doi: 10.1111/j.1478-3231.2012.02819.x. Epub 2012 May 24.

PMID:
22621707
21.

Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.

Hadziyannis SJ.

Aliment Pharmacol Ther. 2012 Jun;35(12):1482. doi: 10.1111/j.1365-2036.2012.05105.x. No abstract available.

22.

Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B.

Hadziyannis SJ.

Aliment Pharmacol Ther. 2012 Apr;35(7):842-3; discussion 843-4. doi: 10.1111/j.1365-2036.2012.05009.x. No abstract available.

23.

Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D.

J Hepatol. 2012 Jun;56(6):1276-82. doi: 10.1016/j.jhep.2011.12.026. Epub 2012 Feb 4.

PMID:
22314423
24.

Treatment of special populations with chronic hepatitis B infection.

Rapti IN, Hadziyannis SJ.

Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):323-39. doi: 10.1586/egh.11.7. Review.

PMID:
21651351
25.

Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C.

Hadziyannis SJ.

Aliment Pharmacol Ther. 2011 Jul;34(1):102-3. doi: 10.1111/j.1365-2036.2011.04680.x. No abstract available.

26.

Effect of antiviral therapy on the immunohistochemical expression of bcl-xL and bax protein in patients with HBeAg-negative chronic hepatitis B.

Cholongitas E, Papatheodoridis GV, Manesis EK, Petraki K, Tiniakos D, Hadziyannis SJ.

J Med Virol. 2011 Jul;83(7):1165-71. doi: 10.1002/jmv.21780.

PMID:
21567420
27.

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, Cacoub P, Eslam M, Lee SS.

J Hepatol. 2011 Jun;54(6):1250-62. doi: 10.1016/j.jhep.2010.11.016. Epub 2010 Dec 8. Review.

28.

High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma.

Dalagiorgou G, Vassilaki N, Foka P, Boumlic A, Kakkanas A, Kochlios E, Khalili S, Aslanoglou E, Veletza S, Orfanoudakis G, Vassilopoulos D, Hadziyannis SJ, Koskinas J, Mavromara P.

J Gen Virol. 2011 Jun;92(Pt 6):1343-51. doi: 10.1099/vir.0.023010-0. Epub 2011 Feb 9.

PMID:
21307221
29.

Milestones and perspectives in viral hepatitis B.

Hadziyannis SJ.

Liver Int. 2011 Jan;31 Suppl 1:129-34. doi: 10.1111/j.1478-3231.2010.02406.x. Review.

PMID:
21205150
30.

Natural history of chronic hepatitis B in Euro-Mediterranean and African countries.

Hadziyannis SJ.

J Hepatol. 2011 Jul;55(1):183-91. doi: 10.1016/j.jhep.2010.12.030. Epub 2011 Jan 14. Review. Erratum in: J Hepatol. 2013 May;58(5):1062.

31.

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S.

J Hepatol. 2011 Jul;55(1):69-75. doi: 10.1016/j.jhep.2010.10.032. Epub 2010 Nov 23.

PMID:
21145856
32.

The natural history of chronic HBV infection and geographical differences.

Liaw YF, Brunetto MR, Hadziyannis S.

Antivir Ther. 2010;15 Suppl 3:25-33. doi: 10.3851/IMP1621. Review.

PMID:
21041901
33.

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.

Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, Zeuzem S.

J Hepatol. 2010 Jun;52(6):832-8. doi: 10.1016/j.jhep.2010.01.030. Epub 2010 Mar 15.

PMID:
20385421
34.

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.

Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P.

Hepatology. 2010 Feb;51(2):388-97. doi: 10.1002/hep.23340.

PMID:
19918980
35.

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.

Reddy KR, Messinger D, Popescu M, Hadziyannis SJ.

J Viral Hepat. 2009 Oct;16(10):724-31. doi: 10.1111/j.1365-2893.2009.01122.x.

PMID:
19486469
36.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.

Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.

PMID:
19338056
37.

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group.

Gastroenterology. 2009 Jun;136(7):2169-2179.e1-4. doi: 10.1053/j.gastro.2009.03.006. Epub 2009 Mar 19.

PMID:
19303414
38.

Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.

Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y; Adefovir Dipivoxil 437 and 438 Study Groups.

J Viral Hepat. 2009 Mar;16(3):203-13. doi: 10.1111/j.1365-2893.2008.01065.x. Epub 2008 Oct 22.

PMID:
19175871
39.

Nonalcoholic fatty liver disease: from clinical recognition to treatment.

Sevastianos VA, Hadziyannis SJ.

Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):59-79. doi: 10.1586/17474124.2.1.59. Review.

PMID:
19072371
40.

Telbivudine in the treatment of chronic hepatitis B.

Hadziyannis SJ, Vassilopoulos D.

Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):13-22. doi: 10.1586/17474124.2.1.13. Review.

PMID:
19072366
41.

Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.

Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM.

Am J Gastroenterol. 2008 Aug;103(8):1981-8. doi: 10.1111/j.1572-0241.2008.01957.x.

42.

Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B.

Vassilopoulos D, Rapti I, Nikolaou M, Hadziyannis E, Hadziyannis SJ.

J Viral Hepat. 2008 Nov;15(11):817-26. doi: 10.1111/j.1365-2893.2008.00996.x. Epub 2008 Jun 11.

PMID:
18554242
43.

The role of entecavir in the treatment of chronic hepatitis B.

Dimou E, Papadimitropoulos V, Hadziyannis SJ.

Ther Clin Risk Manag. 2007 Dec;3(6):1077-86.

44.

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.

Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ.

J Viral Hepat. 2008 Feb;15(2):129-36. doi: 10.1111/j.1365-2893.2007.00901.x.

PMID:
18184196
45.

Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis.

Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ.

Eur J Gastroenterol Hepatol. 2008 Jan;20(1):5-9.

PMID:
18090982
46.

Old and emerging therapies in chronic hepatitis C: an update.

Deutsch M, Hadziyannis SJ.

J Viral Hepat. 2008 Jan;15(1):2-11. Review.

PMID:
18088238
47.

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.

Lim SG, Marcellin P, Tassopoulos N, Hadziyannis S, Chang TT, Tong M, Sievert W, Hu P, Arterburn S, Brosgart CL; International Investigator Groups for Studies 437 and 438.

Aliment Pharmacol Ther. 2007 Nov 15;26(10):1419-28.

48.

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.

Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S.

Liver Int. 2008 Jan;28(1):61-71. Epub 2007 Oct 25.

PMID:
17971091
49.

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.

Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C; HENCORE Group.

J Viral Hepat. 2007 Aug;14(8):556-63.

PMID:
17650289
50.

Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state".

Hadziyannis SJ.

Hepatol Int. 2007 Jun;1(2):281-4. doi: 10.1007/s12072-007-9004-7. No abstract available.

Supplemental Content

Loading ...
Support Center